IMMUNITYBIO, INC. (IBRX) Operating margin 2016–2025
IMMUNITYBIO, INC. (IBRX) operating margin by fiscal year — reported operating income divided by reported revenue.
-226.0%FY2025 · since FY2016: -282954.5% → -226.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -226.0% | +2108.2 pp |
| FY2024 | -2334.2% | +55905.3 pp |
| FY2023 | -58239.5% | +88134.6 pp |
| FY2022 | -146374.2% | -111012.3 pp |
| FY2021 | -35361.9% | +1147.2 pp |
| FY2020 | -36509.1% | -29413.2 pp |
| FY2019 | -7095.9% | +202242.4 pp |
| FY2018 | -209338.3% | +10928.4 pp |
| FY2017 | -220266.7% | +62687.9 pp |
| FY2016 | -282954.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →